Nuclera Acquires E Ink Digital Microfluidics Unit
12.5.2021 15:53:00 EEST | Business Wire | Press release
Nuclera, a fast-growing biotech company developing enzymatic protein and gene synthesis technologies, and E Ink , the leading innovator of electronic ink technology, are pleased to announce the acquisition of E Ink’s digital microfluidics unit into the newly formed US subsidiary of Nuclera. Combining the technologies of the two companies will enable the delivery of a revolutionary desktop protein and gene “bioprinter” with breakthrough speed and convenience for researchers in human health, agriculture, and other markets of global importance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210512005575/en/
Nuclera desktop bioprinter powered by digital microfluidic technology. (Photo: Business Wire)
Nuclera has been working in a strategic partnership with E Ink since 2018 to deploy Nuclera’s proprietary biopolymer synthesis technologies on E Ink’s digital microfluidic devices. Instead of the physical channels found in conventional microfluidics, digital microfluidics uses electronic signals to guide microdroplets. When combined with Nuclera biopolymer synthesis, this advanced lab-on-a-chip technology will enable a user to digitally program the next day bioprinting of proteins and genes on a desktop device. The result is a bioprinter that gives unprecedented access to biology. Commercialization is expected in 2022.
In the transaction, E Ink will contribute intellectual property, equipment, and highly specialized scientists and engineers. Reciprocally, E Ink will become the largest strategic shareholder in Nuclera. The resulting Nuclera US subsidiary will be co-located within the E Ink Innovation Center in Billerica, MA, a short distance from the growing biotech technology hub in Cambridge, MA. The combination of these two efforts into one company will further increase the rate of development, commercialization, and adoption of this ground-breaking product as well as consolidate the intellectual property position. E Ink will continue to be a strategic supplier to Nuclera for key electronic components of Nuclera’s desktop bioprinter.
Dr. Michael Chen, Co-founder and CEO of Nuclera, commented: “Our partner, E Ink, made reading accessible by printing words with electronic ink. We are proud to work with E Ink to make biology accessible by printing biology with digital microfluidics. This acquisition allows Nuclera to combine the biological with the digital in one product and under one roof. We now look forward to further strengthening our strategic partnership with E Ink through joint R&D, manufacturing, and product development projects.”
Dr. Michael McCreary, Chief Innovation Officer of E Ink said: “This spinout and ongoing relationship with Nuclera gives E Ink the opportunity to leverage our knowledge and capabilities in electronic paper technology into the growing biotechnology sector which has increasingly critical importance to the current and future challenges in global health and sustainability. We are pleased to be able participate in this market through an equity stake in Nuclera and look forward to the continuing relationship as a strategic supplier to and equity partner with Nuclera.”
For more information, about Nuclera, visit https://www.nuclera.com.
About Nuclera
Nuclera is the leading pioneer in making biology accessible through desktop enzymatic protein and gene synthesis. Headquartered in Cambridge, UK, Nuclera was founded in 2013 by four PhD students at the University of Cambridge who were frustrated by the inaccessibility of biology. Nuclera has since grown to fifty-seven employees across two continents as the Company delivers on its founders’ vision to make biology accessible to everyone through desktop bioprinting. With desktop bioprinting, researchers and scientists will be empowered to take control of biology through streamlined access to a next-day supply of proteins and genes. Three exciting Nuclera technologies protected by 45+ patents enable Nuclera’s desktop bioprinter: enzymatic protein synthesis, enzymatic gene synthesis, and digital microfluidics. The combination of these technologies in a deployable desktop bioprinting platform create an unprecedented one-stop shop ecosystem that enables Nuclera to provide consistent biological workflows, products, and information to its customers. To be a part of Nuclera’s effort or to simply learn more, please visit www.nuclera.com.
About E Ink Holdings
E Ink Holdings Inc. (8069.TW), based on technology from MIT’s Media Lab, has transformed and defined the eReader market, enabling a new multi-billion dollar market in less than 10 years. E Ink’s low power products are ideal for IoT applications ranging from retail, home, hospital, transportation and more, enabling customers to put displays in locations previously impossible. The Company’s corporate philosophy aims to deliver revolutionary products, user experiences and environmental benefits through advanced technology development. This vision has led to its continuous investments in the field of ePaper displays as well as expanding the use of its technologies into a number of other markets and applications including smart packaging and fashion. Its Electrophoretic Display products make it the worldwide leader for ePaper. Its Fringe Field Switching (FFS) technologies are a standard for high-end LCD displays and have been licensed to all major liquid crystal display makers in the world. Listed in Taiwan's Taipei Exchange (TPEx) and the Luxembourg market, E Ink Holdings is now the world's largest supplier of ePaper displays. For more information please visit www.eink.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210512005575/en/
Contact information
Nuclera:
Andrew Fellows; E: andrewf@alto-marketing.com; T: +44(0)1489 557672
Direct Nuclera media enquiries; E: media@nuclera.com
E Ink:
Anna Halstead, Racepoint Global, 617-624-3492, eink@racepointglobal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
UPS Announces Agreement to Acquire Smartways Logistics17.11.2026 23:00:00 EET | Press release
UPS (NYSE: UPS) today announced it has entered into an agreement to acquire Smartways Logistics (Smartways), a healthcare logistics provider serving Australia and New Zealand. Once completed, the acquisition will enhance UPS Healthcare’s time-critical transportation capabilities in the region. Smartways enables healthcare customers to move critical shipments quickly and reliably, with specialized services for life sciences, medical devices, clinical trials and radiopharmaceuticals. The acquisition will build on UPS Healthcare’s ability to deliver for customers with urgent and complex logistics needs, while expanding the services available in Australia, New Zealand and the Asia Pacific region. “As healthcare becomes increasingly complex, logistics plays an even more critical role. It takes specialized capabilities and precision at every step to help vital healthcare products reach patients safely, reliably and when they’re needed,” said Wilfredo Ramos, UPS EVP and Chief International, H
Spatial Announces Release 2027 1.0 with New Enhancements Across CAD Modeling, Interoperability, Data Preparation, and Meshing17.11.2026 21:10:00 EET | Press release
Spatial Corp., the leading software development kit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, today announced the availability of its 2027 1.0 Release. This latest release introduces new capabilities and enhancements across Spatial's 3D ACIS Modeler, CGM Modeler, 3D InterOp, Data Prep and CSM/CVM product lines. Designed to improve efficiency, flexibility and robustness across CAD modeling, interoperability, data preparation and simulation workflows, the release delivers enhanced geometry processing, expanded modeling capabilities, improved CAD translation and advances in mesh generation for a better workflow coverage. 3D ACIS Modeler Enhanced Blending (Filleting) The 3D ACIS Modeler introduces support for asymmetric fixed-width blends with a conic cross-section, providing users with finer control over smooth transitions between edges. This enhancement builds on the symmetric fixed-width blend with a conic cross-section capabilit
Global EV Alliance Survey: EV Drivers Identify Myths and Misconceptions as the Biggest Barrier to Adoption17.11.2026 20:00:00 EET | Press release
Myths and misconceptions about electric cars, from battery lifespan and fire risk to grid collapse, are the biggest barrier to EV adoption, according to respondents to the annual Global EV Driver Survey. The 2026 survey draws on responses from more than 29,500 EV drivers across 34 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117539716/en/ MYTHS. Battery lifespan (72%), fire risk (58%) and grid collapse (45%) top the list of EV myths reported by respondents to the 2026 Global EV Driver Survey, which gathered responses from more than 29,500 EV drivers across 34 countries. “The EV transition is not just an infrastructure or affordability challenge. It is also an information challenge. Outdated information and misconceptions continue to influence decisions long after the technology has moved on,” says Ellen Hiep, from the Steering Committee of the Global EV Alliance (GEVA). Myths the greatest barrier Asked to ide
KILL Trulioo’s Global Risk Platform Unlocks Device and Behavioral Intelligence Via Bureau Partnership17.11.2026 20:00:00 EET | Press release
Trulioo requests that their press release NewsItemId: 20261117163539 “Trulioo’s Global Risk Platform Unlocks Device and Behavioral Intelligence Via Bureau Partnership” be killed. The release was issued in error by Trulioo.
TreeFrog Therapeutics Appoints James Sterling as Chief Financial Officer17.11.2026 19:04:00 EET | Press release
TreeFrog Therapeutics, a biotechnology company developing scalable cell therapies built on its proprietary C-Stem™ technology, today announced the appointment of James Sterling as Chief Financial Officer, effective November 1, 2026. James joins TreeFrog’s executive leadership team and reports to Mark Rothera, President and Chief Executive Officer. He oversees finance, investor relations and corporate development as the company enters its next phase of growth. “I am delighted to welcome James to TreeFrog. James brings a valuable combination of biotech CFO and Wall Street experience that supports our ambitions to develop TreeFrog into a key enabling partner and drug developer in the regenerative medicines field,” said Mark Rothera, President and Chief Executive Officer of TreeFrog Therapeutics. James contributes deep experience in corporate finance, capital markets and strategic planning across therapeutics and diagnostics. Recently, he served as Chief Financial Officer of Bluebird Bio (
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
